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ABSTRACT
The IUPHAR/BPS Guide to PHARMACOLOGY
(www.guidetopharmacology.org) is an open-access,
expert-curated database of molecular interactions
between ligands and their targets. We describe
significant updates made over the seven releases
during the last two years. The database is notably
enhanced through the continued linking of relevant
pharmacology with key immunological data types as
part of the IUPHAR Guide to IMMUNOPHARMACOL-
OGY (www.guidetoimmunopharmacology.org) and
by a major new extension, the IUPHAR/MMV
Guide to Malaria PHARMACOLOGY (www.
guidetomalariapharmacology.org). The latter has
been constructed in partnership with the Medicines
for Malaria Venture, an organization dedicated to
identifying, developing and delivering new antimalar-
ial therapies that are both effective and affordable.
This is in response to the global challenge of over
200 million cases of malaria and 400 000 deaths
worldwide, with the majority in the WHO Africa
Region. It provides new pharmacological content,
including molecular targets in the malaria parasite,
interaction data for ligands with antimalarial activity,
and establishes curation of data from screening
assays, used routinely in antimalarial drug discov-
ery, against the whole organism. A dedicated portal
has been developed to provide quick and focused
access to these new data.
INTRODUCTION
The International Union of Basic and Clinical Phar-
macology (IUPHAR) and the British Pharmacological
Society (BPS) have jointly developed the Guide to
PHARMACOLOGY (shortened to GtoPdb) from the
antecedent IUPHAR-DB, a resource focused on recep-
tors and channels that was first compiled in 2003 (1–3),
and the BPS ‘Guide to Receptors and Channels’ (4), a
compendium, providing concise overviews of the key
properties of a wider range of targets than those covered
in IUPHAR-DB. Incorporating these two resources,
GtoPdb first came online in 2011, and expanded over
the next 4 years, increasing its coverage of target fam-
ilies and quantitative target-ligand interactions. Expert
guidance and oversight is maintained through the Nomen-
clature Committee of the International Union of Basic
and Clinical Pharmacology (NC-IUPHAR) and its 109
subcommittees. From 2015, it extended into the priority
area of immunopharmacology through the Wellcome-
trust funded IUPHAR Guide to Immunopharmacology
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(GtoImmuPdb; www.guidetoimmunopharmacology.org)
(5–7). The funding period for GtoImmuPdb concluded
in October 2018, at which point the extension was
officially launched at a focused immunopharmacol-
ogy meeting, the report of which is available here
(https://www.guidetoimmunopharmacology.org/pdfs/
Edinburgh Immunoparmacology Meeting Report 2018.
pdf). GtoImmuPdb delivers a knowledge base that con-
nects immunology with pharmacology (8), providing vital
support to the research and development of drugs targeted
at modulating immune, inflammatory or infectious com-
ponents of disease. In the preceding ∼20 years, increasing
numbers of antibodies and small molecule drugs that
target the immune system have been approved as licensed
medicines (Figure 1), and this corroborates the importance
of immunopharmacology. The merit of extending GtoPdb
into immune-relevant areas is strengthened by the part-
nership between IUPHAR and the International Union of
Immunological Sciences (IUIS) to create standard tools
and nomenclature.
Since our 2018 NAR publication (7), we have undertaken
a further extension of the database; this time to include new
types of data relevant to malaria pharmacology. Malaria
is a major global health challenge with a disproportionate
impact on resource-limited countries. In 2017, there were
an estimated 219 million cases of the disease, leading to
435 000 deaths worldwide, with over 90% of these occur-
ring in the World Health Organization’s Africa Region (9).
Action is taken against the spread and progress of the dis-
ease at many levels, from control of the mosquito vector to
prevention and treatment with antimalarial drugs (10). Re-
sistance to these drugs has emerged in many regions of the
world, and strenuous efforts are being made to develop al-
ternative drugs or vaccines. TheMedicines forMalaria Ven-
ture (MMV; www.mmv.org) is an international product de-
velopment partnership, dedicated to identifying, developing
and delivering new antimalarial therapies that are both ef-
fective and affordable for the communities they are intended
to protect (11). In the last twenty years, MMV and their
partners have developed thirteen new medicines, some spe-
cialized for paediatric use or use in pregnant women, and
have taken over stewardship of some drug development pro-
grammes from the Drugs for Neglected Diseases Initiative
(www.dndi.org) (12–14). Recognizing the value of having a
high-quality expert-curated database when designing drug
development strategies, IUPHAR and MMV have collabo-
rated to create the Guide to Malaria PHARMACOLOGY
(abbreviated to GtoMPdb), a web resource specifically de-
signed for malaria pharmacology.
This paper summarizes the main updates to the core
GtoPdb and GtoImmuPdb, and then discusses in more de-
tail the major new extension for malaria pharmacology.
GUIDE TO PHARMACOLOGY AND IMMUNOPHAR-
MACOLOGY CURATION AND EXPANSION
The GtoPdb remains unique in its approach to
curation, which involves expert judgement at all
stages. Our ∼100 NC-IUPHAR subcommittees
(https://www.guidetopharmacology.org/GRAC/
ContributorListForward#contributors), comprising
∼560 scientists worldwide, when combining their knowl-
edge and expertise with that of our in-house curation team
(www.guidetopharmacology.org/about.jsp#curation),
providing a robust model of content selection and quality
control.
Curation and content
Since our last update in 2018 (7), the curation effort
has focused on immunopharmacology. In addition to in-
corporating new immuno-relevant material, existing con-
tent has been enriched through annotating against im-
munological data types (described below). The selection
of content for curation was supported through the iden-
tification of key articles and literature reviews by NC-
IUPHAR subcommittees. The focus was on immunol-
ogy and inflammation literature that identified lead com-
pounds, their molecular targets and contained evidence of
pharmacological modulation and relevance to human dis-
ease. Other useful resources include pharmaceutical com-
panies’ declared development programmes, key papers cir-
culated on Twitter and analysis of patents to identify
pharmacological data beyond peer-reviewed publications.
We also review clinical trial registries and applications to
the WHO for new INNs (International Nonproprietary
Name) (which provides an indication of developments in
the immunity/inflammation/immuno-oncology fields), and
monitor new drug approvals.
Targets. The expansion in GtoPdb content is sum-
marised in Table 1. Individual targets in GtoPdb use
a UniProtKB/SwissProt (15) Accession as their primary
identifier and are organised into hierarchical target fami-
lies. These are organised into top-level target classes (Table
1A). GtoPdb contains 1781 human protein targets with cu-
rated ligand interactions (Table 1C), 1525 of these targets
have quantitative binding data. If the count of interactions
is restricted to just those human targets with quantitative
binding data to an approved drug, these number 638 inter-
actions, 329 of which are cases where the protein is desig-
nated as the primary target of that drug (Figure 2).
The curation effort for immunopharmacology has
seen updates to established targets such as histamine
receptors (https://www.guidetoimmunopharmacology.
org/GRAC/FamilyDisplayForward?familyId=33)
and anti-histamine drugs, glucocorticoid recep-
tors (https://www.guidetoimmunopharmacology.org/
GRAC/ObjectDisplayForward?objectId=625&familyId=
98&familyType=NHR) and anti-inflammatory glu-
cocorticosteroid drugs, cyclooxygenase enzymes
(https://www.guidetoimmunopharmacology.org/GRAC/
FamilyDisplayForward?familyId=269) and NSAID drugs,
and pattern recognition, cytokine and chemokine recep-
tor families. Families of pattern recognition receptors
that were previously absent from the GtoPdb have been
added (16). Given the pharmaceutical industry’s interest
in harnessing the power of the immune system against
cancer (immuno-oncology), curation effort was applied
to include the novel areas of endogenous immune check-
point proteins and their ligands, and to the addition of
therapeutic immune checkpoint modulators. This allowed
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Figure 1. Growth in approvals of monoclonal antibodies over the last 26 years. Data include approvals for monoclonal antibodies and immunoglobulin
Fc domain-containing fusion proteins that act at human protein targets and which are used to treat human diseases. Approval status is derived from the
FDA (U.S. Food & Drug Administration; https://www.fda.gov), EMA (European Medicines Agency; https://www.ema.europa.eu) and EMC (Electronic
Medicines Compendium; https://www.medicines.org.uk) websites, as well as from published ‘First global approval’ articles, and other online resources.
The earliest approval date is used for each drug. The data set does not include the increasing number of biosimilar products that have been approved in
the last 5–6 years.
Figure 2. Growth of human target interaction data in GtoPdb since 2013.
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Table 1. Guide to Pharmacology data counts for targets, ligands and interactions from database release 2019.4
GtoPdb 2020 (± 2018) GtoImmuPdb 2020 (± 2018)
A. Target class content. Human UniProtKB accession Counts
GPCRs 398 (+3) 100 (+14)
Nuclear Hormone Receptors 48 (0) 8 (+2)
Catalytic Receptors 249 (+6) 114 (+7)
Ion Channels 278 (+4) 40 (+20)
Transporters 539 (+30) 9 (+4)
Enzymes 1212 (+28) 196 (+62)
Other proteins 207 (+33) 103 (+39)
Total number of targets 2932 (+98) 568 (+148)**
B. Ligand category counts
Synthetic organics 6524 (+717) 754 (+305)
Metabolites 585 (+1) 38 (+15)
Endogenous peptides 790 (+8) 197 (+21)
Other peptides including synthetic peptides 1338 (+41) 52 (+15)
Natural products 266 (+19) 15 (+6)
Antibodies 261 (+28) 156 (+35)
Inorganics 39 (+1) 1 (0)
Approved drugs 1442 (+108) 264 (+56)
Withdrawn drugs 71 (+4) 14 (+3)
WHO essential list 193 (+193) 36 (+36)
Ligands with INNs 2353 (+239) 476 (+140)
PubChem CIDs* 7319 (+617) 758 (+274)
PubChem SIDs* 9714 (+736) 1183 (+367)
Total number of ligands 9803 (+825) 1213 (+397)
C. Interaction counts.
Human targets with ligand interactions 1781 (+97) 528 (+138)
Human targets with quantitative ligand interactions 1525 (+166) 452 (+131)
Human targets with approved drug interactions 638 (+75) 212 (+60)
Primary targets*** with approved drug interactions 329 (+16) 116 (+25)
Ligands with target interactions 8464 (+801) 1081 (+363)
Ligands with quantitative interactions 7455 (+739) 880 (+327)
(approved drugs) 925 (+101) 189 (+51)
Ligands with clinical use summaries 2436 (+347) 597 (+174)
(approved drugs) 1439 (+107) 263 (+55)
Number of binding constants 48531 (+2043) -
References 36440 (+4707) -
*Counts taken prior to submitting to PubChem post-2019.4 release.
**604 targets are tagged in GtoImmuPdb, but 36 have no Human UniProtID.
***Primary target indicates the dominant Molecular Mechanism of Action (MMOA).
The table includes a comparison to the figure in the 2018 update (7). Categories are not mutually exclusive, and targets and ligands can fall into more than
one category.
the generation of a new ligand family ‘Immune check-
point modulators’ (https://www.guidetopharmacology.org/
GRAC/FamilyDisplayForward?familyId=969) that pro-
vides users with a single, easy access point to the GtoPdb
list of those drugs that are already in use and many more
currently under clinical or preclinical investigation.
Immunological data types. As previously described (7),
GtoImmuPdb was designed to incorporate immunological
data types and associate these with existing targets and lig-
ands. This enrichment includes immunological processes,
cell types and diseases. The methodology for process and
cell type inclusion was described in our last update but, in
summary, we have used Gene Ontology (17,18) biological
process terms and Cell Ontology (19) cell types to underpin
top-level categories against which we have annotated pro-
tein targets (Table 2). The use of ontologies gives a con-
trolled vocabulary and external identifiers; these support
interoperability. In the case of processes, they also prove
a route to auto-curate some associations via UniProt-GO
(15) associations. Users are able to view detailed lists of tar-
gets associated with the top-level categories, and linked on-
tology terms are listed alongside curator comments on an
individual target’s relevance to immunopharmacology.
Ligands. Our criteria for including ligands continues to
prioritise those that are well characterised (e.g. with trian-
gulation from multiple sources) and that possess quanti-
tative interactions with protein targets (Table 1B). In the
last two years, we have added over 800 new ligands, with
around 48% being relevant to immunopharmacology (re-
flecting the curation focus in this area). We have added a
new ligand category that includes those in the WHO essen-
tial medicine list, currently 193 ligands, 36 of which are in-
cluded in GtoImmuPdb.
To capture novel drugmechanisms that are being pursued
by the pharmaceutical industry, we have selected exemplars
that highlight novel pharmacological approaches that
expand upon existing drug classes. A number of PROTAC
(proteolysis targeting chimera) type drugs are in develop-
ment. Rather than simply acting as inhibitors, PROTACS
direct their protein target to proteasomal degradation. As
examples we have included JH-XI-10-02 (a CDK8 kinase-
directed degrader; www.guidetopharmacology.org/GRAC/
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Table 2. GtoImmuPdb Process andCell Type categories showing the num-
ber of human protein targets in the database annotated with them
Process Annotated human targets
Barrier integrity 49
Inflammation 633
Antigen presentation 142
T cell (activation) 196
B cell (activation) 161
Immune regulation 503
Tissue repair 19
Immune system development 251
Cytokine production & signalling 504
Chemotaxis & migration 256
Cellular signalling 476
Cell type Annotated human targets
B cells 51
Dendritic cells 41
Granulocytes 46
Innate lymphoid cells 6
Macrophages 56
Mast cells 39
Natural killer cells 26
Other T cells 3
Stromal cells 1
T cells 76
LigandDisplayForward?ligandId=9887) and ARD-69 (an
androgen receptor degrader; www.guidetopharmacology.
org/GRAC/LigandDisplayForward?ligandId=10182),
both of which have postulated anti-tumour potential
(20,21).
New classes of anti-inflammatory and analgesic
drugs are also being developed, with examples such
as naproxcinod (a NO-donating naproxen analogue pro-
drug; www.guidetoimmunopharmacology.org/GRAC/
LigandDisplayForward?ligandId=9551) and ATB-
346 (a hydrogen sulfide-releasing naproxen deriva-
tive; www.guidetoimmunopharmacology.org/GRAC/
LigandDisplayForward?ligandId=9534), which have both
progressed to clinical evaluation as novel therapeutics for
arthritis and osteoarthritis, respectively (22,23).
PubChem submissions. The range of powerful utilities
arising from GtoPdb ligand data integration into Pub-
Chem (24) and the rest of the NCBI system (25), includ-
ing PubMed and PDB ligands, has already been described
(7). Users are able to make domain-specific queries related
to both immunopharmacology and malaria pharmacology
via curatorial tagging within the depositor comment sec-
tions in the substance records (SIDs) (Figure 3). This al-
lows queries to be executed from both the PubChem Sub-
stance (SID) and PubChem Compound (CID) interfaces
(26), by using an advanced search of ‘comments’ fields, as
outlined in Table 3. PubChem Substances are community-
provided compounds, and many entries may exist for the
same molecule. Each may contain different information
about the molecule, depending on the information provided
by the submitter. PubChem extracts the unique chemical
structures from Substance records (standardization) and
stores them as PubChemCompounds. This means that sub-
stance records from different data sources about the same
molecule are aggregated in a common Compound record
in PubChem. The wide range of GtoPdb-associated data
mining that can be executed in PubChem is too large to be
expanded in detail but selected worked examples have been
described (27). Informative statistics represented in the 7612
total CIDs (2019.4 release) include the following:
• 66% conform to Lipinski’s Rule-of-Five (28,29) lead-like
property limits.
• 148 entries are unique toGtoPdb as their only annotation
source (as of 1 October 2019).
• 78% have an exact match to an automated patent extrac-
tion source (not all of these are currently claimed struc-
tures but many can be linked to SAR data sets in patent
documents to which links will be added).
• 726 do not have BioAssay Tested results. This means
GtoPdb is the only source of literature-extracted activity
for those compounds.
• 19% have a PDB ligand match.
• 27% have been annotated with the MeSH terms included
in the ‘Pharmacologic Actions’ classification (https://
www.ncbi.nlm.nih.gov/mesh/68020228). By definition we
have thus greatly expanded the annotation of these com-
pounds with pharmacological data.
• 77% have a vendor match.
• 25% do not have a match to PubChem ChEMBL entries.
As mentioned a new ‘Guide to Malaria Pharmacology’
tag has been added to the depositor comments in our Pub-
Chem submission. This means that the set of antimalar-
ial compounds in GtoPdb (2019.4 release) can be retrieved
from PubChem (Figure 4), and specific statistics for 72
CIDs can be generated:
• 44 conform to Lipinski’s Rule-of-Five (28,29) lead-like
property limits.
• 57 have an exactmatch to an automated patent extraction
source.
• 19 do not have BioAssay Tested results.
• 15 have a PDB ligand match.
• Only 27 have been annotated with the ‘Antimalarials’
MeSH term.
• 56 have a vendor match.
• 16 do not have a match in ChEMBL entries.
Website
Disease summary pages. The website has been signifi-
cantly enhanced by the development of disease summary
pages (Figure 5). As part of the GtoImmuPdb extension,
targets have been linked to ligands of immunological rele-
vance to the diseases in which they play a role. The GtoPdb
already contained limited disease information, which in-
cluded pathophysiologies and clinically-relevant mutations
for targets, but it was not organised in a manner to find all
relevant data for each disease easily. The new development
has allowed the consolidation of all the associated data and
to present this to users on a single disease page. In total,
there are over 1000 disease entries in the database linked to
targets and/or ligands. For all diseases, there are external
links to one or more entries in OMIM (30,31), Orphanet
(https://www.orpha.net) and the Disease Ontology (32) and
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gkz951/5613677 by Edinburgh U
niversity user on 12 N
ovem
ber 2019
6 Nucleic Acids Research, 2019
Figure 3. Ligand chloroquine, depositor comments from PubChem substance record (https://pubchem.ncbi.nlm.nih.gov/substance/178102177#section=
Depositor-Comments). Displaying depositor comments added during submission fromGtoPdb. These indicate inclusion in either GtoImmuPdb orGtoM-
Pdb; drug approval status; and curatorial comments.
Table 3. Counts of GtoPdb tagged ligands in PubChem (1 October 2019; data from GtoPdb 2019.4 release)
Query PubChem Substance query SID counts
All ligands in GtoPdb ‘IUPHAR/BPS Guide to PHARMACOLOGY’[SourceName] 9806
Approved drugs AND gtopdb approved 1337
Clinical antibodies AND antibody 258
GtoImmuPdb AND gtopdb immuno 964
GtoMPdb AND gtopdb malaria 72
Query PubChem Compound query CID counts
All ligands in GtoPdb ‘IUPHAR/BPS Guide to PHARMACOLOGY’[SourceName] 7612
Approved drugs SID > CID 1234
GtoImmuPdb SID > CID 798
GtoMPdb SID > CID 72
Apart from the total selected by source, all other CID numbers are retrieved via the ‘Find related data’ > Select PubChem Same Compound (i.e. a SID >
CID conversion).
list any known synonyms, which helps users to cross-check
between different resources.
The target section of the disease summary page displays
information on targets associated with the disease. Ligands
that are associated with the disease, that also have inter-
action data with the target, are listed alongside curato-
rial comments and indications if they are approved drugs.
If there is further data on the targets role and any other
therapeutically-used drugs acting via the target, these are
also displayed.
The ligand section lists all the drugs and other com-
pounds associated with the disease, the majority of which
come from the curation effort for GtoImmuPdb. Users can
expand this section for additional information linking the
ligand to the disease, such as clinical use and bioactivity
comments.
WHO essential medicines. GtoPdb now includes an
additional category of ligands: those currently included
in the World Health Organization (WHO) Model List
of Essential Medicines (21st, 2019; https://www.who.int/
medicines/publications/essentialmedicines/en/). These lig-
ands are displayed under the ‘WHO’ category on our ligand
list page (https://www.guidetopharmacology.org/GRAC/
LigandListForward?type=WHO-essential&database=all)
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Figure 4. Top results returned when searching PubChem Substance for GtoPdb compounds included in GtoMPdb ((‘IUPHAR/BPS Guide
to PHARMACOLOGY’[SourceName]) AND gtopdb malaria; https://www.ncbi.nlm.nih.gov/pcsubstance/?term=(%22IUPHAR%2FBPS+Guide+to+
PHARMACOLOGY%22%5BSourceName%5D)+AND+gtopdb malaria).
and on individual ligand summary pages, inclusion in this
list is marked under the classification section.
Move to hypertext transfer protocol secure (HTTPS). In
order to improve and protect the integrity of GtoPdb, we
have completed the transition from HTTP to HTTPS. This
helps to make end user communication more secure.
Chemicalize Pro (ChemAxon). A key feature of the
website is the ability to perform searches by chemical
structure (http://www.guidetopharmacology.org/GRAC/
chemSearch.jsp). The chemical structure search tool utilises
Marvin JS by ChemAxon. In the 2019.1 (January 2019)
release, the API control was updated to use Chemicalize
Pro (https://pro.chemicalize.com/). This update simplifies
the integration of Marvin JS into our website.
Page navigation. Many of the pages on GtoPdb, particu-
larly the detailed target view pages, are rich in information,
requiring users to scroll far down the page, away from the
main menu bar that is used for navigation. We have there-
fore implemented a new drop-down navigation bar, which is
revealedwhen users scroll-down on longer pages. This keeps
key menu items, and most importantly the site search, in fo-
cus at all times.
GUIDE TO MALARIA PHARMACOLOGY
The Guide to Malaria Pharmacology (GtoMPdb) project
was initiated in October 2017, with funding from MMV,
to expand the content of the existing database to include
antimalarial ligands and targets. This required extension of
the GtoPdb to display the new data and to augment exist-
ing search and browse functions. A purpose-built portal has
been developed, in consultation with key opinion leaders in
malaria research, to provide optimized access to the anti-
malarial data. This initiative has enriched the GtoPdb and
will hopefully advance innovation by providing, in a sin-
gle expert-curated database, results from antimalarial drug
discovery programmes and the scientific literature. The full
public release of the GtoMPdb was made in September
2019.
Curation and content
The focus for the GtoPdb has hitherto been the pharma-
cology and immunopharmacology associated with human
non-infectious diseases. Targets identified and validated in
Plasmodium, the genus of protozoan parasite known to
cause malaria, had not previously been included in the
GtoPdb. Indeed, there were very few, if any, data from non-
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Figure 5. GtoPdb disease summary page for chronic lymphocytic leukemia (https://www.guidetoimmunopharmacology.org/GRAC/
DiseaseDisplayForward?diseaseId=218). (A) Summary of disease and counts of associated targets and ligands. (B) Associated target data section.
(C) Associated ligand data section, with expandable drop-down comments.
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Table 4. GtoMPdb data counts for targets, ligands and interactions
(database release 2019.4)
Guide to Malaria Pharmacology Content Breakdown
Targets 30
Ligands 72
Ligands (approved drugs) 19
Ligands (WHO essential lists) 17
Targets with quantitative ligand interactions 20
Targets with approved drug interactions 4
Ligands with interactions 67
Ligands with interaction to known targets 38
Ligands with interaction to unknown targets 34
Ligands with quantitative interactions (approved drugs) 65 (18)
Ligands with clinical use summaries (approved drugs) 39 (19)
mammalian species in the GtoPdb. Similarly, the number
of ligands with antimalarial activity was small. In extend-
ing the parent database to capture data of relevance to
malaria pharmacology our curatorial procedures have been
reviewed, allowing the identification of modifications re-
quired to the database schema and web interface. The sec-
tions below will expand on these aspects but an important
consideration has been to utilize GtoPdb entity IDs rather
than generating a separate identifier system. This is because
malaria pharmacology is a subcategory of pharmacology,
which is in accordance with the approach taken with the
previous GtoImmuPdb expansion. Instead, a project spe-
cific tag has been introduced to identify ligands and targets
of interest to malaria pharmacology and that are to be in-
cluded in the GtoMPdb.
The established curation protocol employed for the
GtoPdb (described in previous updates and reviewed in
(33)) required modest adaptations to allow capture of
antimalarial ligands and targets as database entries. Papers
were selected for curation when they had: an explicit chem-
ical structure and at least one of the following; quantitative
potency for antimalarial activity in vitro, activity data
(where available) against a purified Plasmodium target, and
in vivo and/or clinical data. This content was added with
guidance from a group of scientific advisors and an expert
advisory committee (www.guidetomalariapharmacology.
org/malaria/gtmpAbout.jsp#contributors): expanding to
30 Plasmodium molecular targets and over 70 ligands
annotated with antimalarial activity, including approved
drugs, clinical candidates and research leads. In addition,
antimalarial medicines are presented that were used in
the past but are now either no longer recommended or
are restricted in their use. These medicines have often
become less effective over time because of the emer-
gence and geographical spread of strains of the parasite
that have become resistant to them. A summary of
GtoMPdb data content is provided in Table 4, and full
antimalarial target (www.guidetomalariapharmacology.
org/GRAC/FamilyDisplayForward?familyId=970) and
ligand (www.guidetomalariapharmacology.org/GRAC/
LigandListForward?type=AntiMal&database=all) lists are
accessible on the website.
Targets. Antimalarial targets is a new target family, en-
compassing targets identified and validated in the Plasmod-
ium parasite. It has been introduced as a subfamily un-
der other protein targets, within the hierarchical classifi-
cation of target families used by GtoPdb. In accordance
with GtoPdb targets, individual Plasmodium targets use a
UniProtKB/SwissProt Accession as their primary identi-
fier. The nomenclature adopted is derived from information
available from PlasmoDB (www.plasmodb.org), a genome
database for the genus Plasmodium that is part of the Eu-
PathDB Bioinformatics Resource Center (www.eupathdb.
org) (34,35). The pragmatic decision was taken to link the
gene symbol to the P. falciparum 3D7 reference sequence
(36) at PlasmoDB, although information for other Plas-
modium species and other P. falciparum clones is also cu-
rated. Similarly, UniProt IDs are assigned to antimalar-
ial targets using the P. falciparum 3D7 reference proteome
(www.uniprot.org/proteomes/UP000001450) (15).
Ligands. All GtoMPdb tagged ligands are now included
in the antimalarial ligands family, a new group of related
ligands that has been added to the GtoPdb ligand family
list. In line with GtoPdb curation protocol, most chemical
structures have been resolved to PubChem entries and all
the curated antimalarial compounds have been submitted
to PubChemwhere they acquireGtoPdb-specific Substance
Identifiers (SIDs). The criteria for inclusion of a ligand has
however been adapted because many antimalarial ligands
do not possess quantitative interactions with a known pro-
tein target.
Comparison with ChEMBL content. A major utility
offered by GtoMPdb is the prompt surfacing of new lead
compounds, their metadata and associated molecular
targets from the literature, but its value is also strengthened
by the relative lack of similar open-access resources that
curate data on malaria pharmacology. Indeed, comparing
our coverage with that of ChEMBL (37), highlights a few
distinctions. For our 30 Plasmodium targets, only six have
UniProt IDs in common with ChEMBL. We suggest two
reasons for this, the first being we have picked up more
recent publications. The second is the challenge to assign a
UniProt ID based only on the author’s target description in
their paper. This is compounded by the problem that even
the reference strain P. falciparum 3D7 has only 165 proteins
annotated to the Swiss-Prot standards whereby naming
equivocality is reduced (but cannot be eliminated) but for
all P. falciparum isolates there are over 125 000 sequence
entries. We thus speculate that the targets-in-common be-
tween GtoMPdb and ChEMBL might be higher than the
distinct UniProt IDs indicate. For ligands, the difference
is smaller in that 20% of GtoMPdb structures have no
match in ChEMBL. In some cases, ChEMBL may have
chosen a different isomer, depending on their interpre-
tation of the image in the paper, but we can also once
again attribute some of this difference to the more recent
publications we have extracted. As an example, PubMed
ID:30894487 (38), was published in April 2019 and the lead
(ligand ID 10398; www.guidetomalariapharmacology.org/
GRAC/LigandDisplayForward?ligandId=10398) entered
PubChem via our June 2019 release.
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Modifying the GtoPdb schema for malaria pharmacology
A number of changes have been made to the database struc-
ture and web interface to improve both the capture and pre-
sentation of antimalarial data. To fully describe the activ-
ity and target interactions of antimalarial compounds re-
quires the display of additional information, some of which
is specific for the malaria parasite. We have extended the
database schema andmodified the interactions table display
to accommodate these requirements (see Figure 6A). A new
‘whole organism’ assay type has been introduced to capture
data from the high-throughput whole cell screens used rou-
tinely in antimalarial drug discovery (39). As already men-
tioned, many antimalarial compounds have a poorly under-
stood mechanism of action and an unknownmolecular tar-
get.
The Plasmodium parasite has a complex lifecycle (40),
and the goal to eradicate malaria will require the dis-
covery and development of new antimalarial medicines
that target multiple stages of the parasite lifecycle and
in particular the transmission cycle (39,41,42). Capturing
quantitative interaction data for the activity of an anti-
malarial ligand against the different developmental forms
of the parasite was identified as a key requirement for
the GtoMPdb. With guidance from the group of scien-
tific advisors, a set of top-level lifecycle stages was de-
fined (see www.guidetomalariapharmacology.org/GRAC/
ParasiteLifecycleStagesForward for further details) against
which ligand interactions can now be annotated in the
database. These are collective categories, for one ormore de-
velopmental forms of the parasite, and which form the ba-
sis of organising, navigating and searching for parasitic life-
cycle activity data. The interactions table display has been
modified to include this information (see Figure 6A).
Accessing and viewing antimalarial data
Portal. A new dedicated portal has been developed, giv-
ing open and optimized access to the antimalarial data in
the GtoPdb. In designing and building this portal, we have
drawn on our experience from the GtoImmuPdb project,
with the provision of a dedicated domain for the GtoMPdb
(www.guidetomalariapharmacology.org) and the design of
a distinct identity (logo, menu-bar and colour scheme). In
addition to the existing ligand and target browse/search
functionality available on the parent GtoPdb site, cus-
tomized views of the data have been developed that include
parasite lifecycle and target species activity. These have been
designed in consultation with malaria researchers to deliver
data returns that they find themost useful. Access to all data
is from the menu-bar or from panels on the portal home-
page. The site search, available in the top-right corner of all
database pages, has been extended to incorporate the new
antimalarial data. The search algorithm has also beenmod-
ified for queries from GtoMPdb pages to increase the rank-
ing of results for entities with the malaria project tag. A de-
scription of navigating and viewing data using the GtoM-
Pdb portal is provided in the following subsections.
Targets. The targets panel links directly to the new anti-
malarial targets family. From there, the user can browse and
navigate to individual target pages and find detailed infor-
mation about each target and its interactions. For individual
target pages, the overall style and layout used by the par-
ent database was retained with the intention of providing
a familiar interface for users who are already acquainted
with the GtoPdb. A new comments section has been added,
allowing information of relevance to malaria to be high-
lighted.
Ligands. The ligands panel provides customized access to
the ligand lists page, with tabs for different categories of an-
timalarial ligands in the database, such as approved anti-
malarial drugs and antimalarial ligands with a Target Can-
didate Profile (TCP). The TCP describes the key attributes
of a new molecule from theMMV global malaria portfolio,
as it enters clinical development (41,42).
For individual ligand summary pages, we have again re-
tained the style and layout of the parent database. A new
malaria tab has been implemented (Figure 6B) and this
is displayed on the summary page for GtoMPdb tagged
ligands. This view provides information of relevance to
malaria pharmacology and a separate table containing
TCP information (where this is available). A link to the
GtoPdb ligand family page, with the antimalarial ligands
category highlighted (www.guidetomalariapharmacology.
org/GRAC/LigandFamiliesForward), is available from the
menu-bar.
Parasite lifecycle stages. The parasite lifecycle stages panel
is one of the tailored routes developed for accessing an-
timalarial information in the GtoMPdb. Clicking on the
home page link takes the user to a summary page that in-
cludes general information about the lifecycle of the Plas-
modium parasite and a list of our top-level lifecycle stage
categories. The same list of links to top-level categories is
provided in the parasite lifecycle stages panel and from the
menu-bar. Clicking on one of these categories links to a new
page providing a description of the lifecycle stage and all in-
teractions contained in the database that are associatedwith
it (Figure 7).
Target species. The target species panel is another new
route for accessing antimalarial information. Clicking on
the target species home page link takes the user to a sum-
mary page that includes background information about
Plasmodium species that are of clinical or experimental im-
portance, links to individual pages for Plasmodium species
for which data are presented in the GtoMPdb, and a list of
useful resources. The same list of species links is provided
in the target species panel and from the menu-bar. Clicking
on one of these species links takes the user to a new page
providing a description of the species and all interactions
contained in the database that are associated with it (Fig-
ure 8).
Resources. The portal homepage provides links to
a number of supplementary resources, including a
news panel and links to the GtoPdb Twitter feed.
Help pages developed specifically for the GtoM-
Pdb (www.guidetomalariapharmacology.org/malaria/
gtmpHelpPage.jsp) can be accessed from the menu-bar. In
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Figure 6. GtoMPdb ligand summary page illustrating new interface features. (A) The modified interactions table provides data from whole cell as-
says, with information available for the parasite lifecycle stage activity (given in the dropdown information for each row) and Plasmodium species
(pop-up window in the species column). The table shown is for a ligand with an unknown target (ganaplacide, GtoPdb Ligand ID 9946; https://www.
guidetomalariapharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=9946). (B) The malaria tab displays curator comments of par-
ticular relevance to malaria, including summary information about the potential target or mechanism of action, and a table containing TCP details (exam-
ple shown is (+)-SJ733, GtoPdb Ligand ID 9723; https://www.guidetomalariapharmacology.org/GRAC/LigandDisplayForward?tab=malaria&ligandId=
9723#malaria).
addition, popup windows provide tailored help for each
of the data panels on the portal homepage and have been
made available on other pages for data fields that require
further explanation.
COLLABORATIONS, CONNECTIVITY AND INTEROP-
ERABILITY
Elixir-UK
GtoPdb remains one of the ELIXIR-UK node services,
under its human health and disease strategic theme
(https://elixiruknode.org/human-health-and-disease/). Our
involvement with ELIXIR-UK brings closer ties with other
key UK bioinformatics resources and facilitates collabo-
ration on the use of standard ontologies and identifiers.
This is valuable as we continue seeking to ensure GtoPdb
is a FAIR-compliant (Findable, Accessible, Interoperable,
Reusable) resource.
Immunopaedia
We have recently begun to build links with Immunopaedia
(www.immunopaedia.org.za), an open-access online plat-
form for immunology education (43). The resource aims to
improve engagement between core immunology and clini-
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Figure 7. Example of a parasite lifecycle page, here the Plasmodium liver stage (https://www.guidetomalariapharmacology.org/GRAC/
ParasiteLifecycleDisplayForward?stageId=1), developed specifically for GtoMPdb.
cal practice, and it is the official International Union of Im-
munological Societies (IUIS) learning site. Immunopaedia
provides clinical case studies to help highlight immunologi-
cal concepts, online courses to support teaching and learn-
ing in immunology, and also provides information on treat-
ment and diagnostics on infectious diseases. We have added
links from ligand summary pages to relevant case studies
at Immunopaedia. Immunopaedia has reciprocally imple-
mented links from a number of case studies to the corre-
sponding GtoPdb target and ligand pages.
SynPharm
Links are now in place on appropriate target
and ligand pages to SynPharm (http://synpharm.
guidetopharmacology.org/), a database of drug-responsive
protein sequences (44), derived from the interactions in
GtoPdb and using data from the RCSB Protein Data
Bank (PDB) (45). SynPharm is an open-access, web-based
tool that integrates pharmacological and ligand–protein
binding information to present data on the drug-binding
domains of proteins in a manner useful to synthetic biolo-
gists. Its strengths as a bioinformatic tool to facilitate the
design of drug-responsive proteins are demonstrated in a
recent paper that discusses engineering druggability into
the Cpf1 effector of CRISPR gene editing (46).
Tocris
As a trusted supplier of life science reagents, we have estab-
lished a sponsorship collaboration with Tocris Bioscience
(https://www.tocris.com/), to add links to their catalogue
from GtoPdb ligand summary pages. Currently there are
1357 ligands with links to the Tocris website records for
these compounds.
Database links and interoperability
We maintain a list of database link-outs from GtoPdb
target and ligand pages and this can be viewed at www.
guidetopharmacology.org/helpPage.jsp#databaseLinks.
Since 2018, we have added links to Immunopaedia and
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Figure 8. Example of an individual target species page, here showing Plasmodium falciparum (https://www.guidetomalariapharmacology.org/GRAC/
MalariaTargetSpeciesDisplayForward?speciesId=103), developed specifically for GtoMPdb.
PlasmoDB, and updated our out-links to ChEMBL (37),
thereby adding ∼800 new links.
The GtoPdb has recently been included in the External
Links service at Europe PMC (EPMC) (https://europepmc.
org/LabsLink). On EPMC pages, links to target and ligand
entries have been added to the papers curated by GtoPdb
that include a quantitative description of the ligand–target
interaction. It is possible to retrieve all these references
at EMPC by running an ‘Advanced Search’ and select-
ing ‘IUPHAR/BPS Guide to Pharmacology’ from the ‘Ex-
ternal Links’ drop-down list (LABS PUBS:‘1969’) as the
cross-reference query. It is possible for this set of publica-
tions to be further combined, as Boolean-type queries, with
all other types of EPMC indexing including Bibliographic
Fields, Filters, Data Links, External Links and Annota-
tions.
External profile
Disseminating information about GtoPdb (as one of
our routes to impact) is done in a number of ways.
We regularly publish peer-reviewed articles covering
database updates, curation challenges and guides to
accessing data (https://www.guidetopharmacology.org/
nciupharPublications.jsp#Database). We also share posters
and presentations made by the team at national and inter-
national conferences. These are collated on our SlideShare
account (www.slideshare.net/GuidetoPHARM). We reg-
ularly use Social Media (Twitter (@GuidetoPHARM),
Facebook and LinkedIn) to announce database updates,
publications of interest and alert followers to upcoming
events. Our blog is used to provide detailed descriptions of
database releases, technical descriptions of developments
and commentaries on hot topics in pharmacology (https:
//blog.guidetopharmacology.org/category/hot-topics/). We
track user interactions via Google Analytics, which shows
a monthly average of ∼33 600 sessions from ∼22 000 users.
The Concise Guide to PHARMACOLOGY 2017/18 (47)
is the third edition in a series of biennial publications
containing concise overviews of nearly 1800 human drug
targets - the fourth edition is due for publication in late
2019.
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FUTURE DIRECTIONS
From its origins in 2011, the GtoPdb has become rec-
ognized as an authoritative, open resource that provides
expert-curated molecular interactions between ligands and
targets encoded by the human genome. As described in this
update, the unique model of content selection and quality
control provided by the GtoPdb has recently been extended
to capture data for the priority areas of immunopharma-
cology andmalaria pharmacology. In the immediate future,
work will continue on increasing the content of both the
GtoImmuPdb and GtoMPdb. For the GtoMPdb, new data
curation will continue until June 2020, with a focus on ex-
panding the antimalarial targets family.Wewill also address
the need to provide a hierarchical organization of subcate-
gories for this expanded family.
The initial development phase for theGtoMPdbdatabase
and web-application is now complete, but it will continue to
be supported and maintained through core GtoPdb devel-
opment resources. We will be seeking feedback from users
and we aim to implement the most useful suggested im-
provements to the interface. In addition, work is planned to
include all data for the GtoMPdb in our web-services out-
put, and to provide advanced search tools specific to the
malaria project.
For the core database, we are also working with
Bioschemas (http://bioschemas.org/) (48) to add
schema.org semantic mark-up to GtoPdb, which would
make it simpler for search engines to index the web-
site, and make it easier to collate and analyse the
data. Our current focus is on implementing mark-up
on all ligand summary pages, including properties
from the Bioschemas MolcularEntity profile (https:
//bioschemas.org/specifications/drafts/MolecularEntity).
In the longer term, we are exploring other key areas of
pharmacological interest with the intention of providing
further expansion of the GtoPdb.
DATA ACCESS
GtoPdb, GtoImmuPdb and GtoMPdb are avail-
able online at www.guidetopharmacology.org,
www.guidetoimmunopharmacology.org and
www.guidetomalariapharmacology.org, respectively.
All three resources are licensed under the Open
Data Commons Open Database License (ODbL)
(www.opendatacommons.org/licenses/odbl/) and the
contents are licensed under the Creative Commons At-
tribution ShareAlike 4.0 International (CC BY-SA 4.0,
https://creativecommons.org/licenses/by-sa/4.0/). Advice
on linking to us and for accessing and downloading data
are provided here: https://www.guidetopharmacology.
org/linking.jsp. GtoPdb aims to make three to four
public database releases per year; the data summaries
and statistics reported in this paper are from release
2019.4 (September 2019). Our downloads page (avail-
able from www.guidetopharmacology.org/downloads.jsp)
provides a dump file of the full PostgreSQL database
(http://www.postgresql.org/), in addition to a number of
specific download files for targets, ligands, interactions,
peptides, and (new in 2019) endogenous/natural ligands.
We also provide RDF flat files, which users can load
into a local triple store and perform SPARQL queries
across the data. Our REST web services are available at
http://www.guidetopharmacology.org/webServices.jsp and
provide computational access to data in JavaScript Object
Notation (JSON) format. We continue to respond to users’
requests and have extended the web-services to include
transduction mechanisms, selectivity data and adding
Ensembl Gene IDs into the interaction download. We
encourage users to communicate with us if they download
data in any format, both for further advice and so we are
aware of applications using GtoPdb data.
CITING THE RESOURCE
Please cite this article rather than the previous ones; ci-
tation advice for specific target pages appears on the
website. Please refer to our resources on first mention
by full correct name (IUPHAR/BPS Guide to PHAR-
MACOLOGY, IUPHARGuide to IMMUNOPHARMA-
COLOGY, IUPHAR/MMVGuide toMALARIAPHAR-
MACOLOGY) including the capitalization. For subse-
quent abbreviation, please use GtoPdb, GtoImmuPdb
and GtoMPdb, specifying the release version number
(this can be found on our About page (http://www.
guidetopharmacology.org/about.jsp#content)).
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